Drugs With Semaglutide Linked to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Two large medical studies from Denmark presented in December 2024 provide more evidence of a link between Ozempic and an eye condition called NAION (non-arteritic anterior ischemic optic neuropathy), finding that people who used Ozempic have more than a two-times increased risk of developing this serious eye side effect, which can cause vision loss and blindness. These two Danish medical studies serve to confirm what was first reported in a July 2024 medical journal article, that Wegovy, Rybelsus, and Ozempic are linked to eye problems because semaglutide, which is the active ingredient for each of these three drugs, is associated with NAION.
Eye-related side effects of Ozempic, Wegovy, and Rybelsus with possible vision loss is a drug safety issue for these semaglutide-containing medications from Novo Nordisk that is generally unknown to many. Here is what you need to know:
- Ozempic, Wegovy, and Rybelsus are drugs with semaglutide as their active ingredient.
- Semaglutide has been linked to nonarteritic anterior ischemic optic neuropathy (NAION).
- NAION is sometimes referred to as an “eye stroke,” and it occurs when there is a lack of sufficient blood flow to the optic nerve.
- NAION typically causes sudden vision loss and, in severe cases, can lead to blindness.
- There are currently no proven treatments for NAION.
The current drug labels for Ozempic, Wegovy, and Rybelsus do not warn about eye-related side effects, such as possible vision loss. We are looking into possible drug injury lawsuits for patients who developed eye-related side effects of Ozempic, Wegovy, and Rybelsus from Novo Nordisk. Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients with vision loss due to nonarteritic anterior ischemic optic neuropathy (NAION) would be filed against Novo Nordisk for its failure to warn about any eye problems such as vision loss. And because there are no warnings in the current drug labels about an increased risk of eye-related side effects for Ozempic, Wegovy, and Rybelsus, those drug injury cases would not be filed against patients’ doctors.
Free Case Evaluation for Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus
We encourage you to submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Ozempic, Wegovy, or Rybelsus drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Most Recent Article About Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus With Vision Loss
NAION With Ozempic, Wegovy, Mounjaro, or Zepbound Use: Why Are There Still No Warnings?
Numerous medical studies have been published in the past couple of years about non-arteritic anterior ischemic optic neuropathy (NAION) with Ozempic, Wegovy, Mounjaro, or Zepbound use resulting in sudden vision loss.
Despite this drug safety information, the current Prescribing Information documents or drug labels in the US for these four increasingly popular drugs still do not have any warnings for doctors or patients about NAION and vision loss as of October 2026.
To read more of this article, click below:
Before we point out two recent medical news articles relevant to NAION with Ozempic, Wegovy, Mounjaro, or Zepbound use, and whether their respective drug labels should have NAION and vision loss warnings, here are a couple of earlier pieces we wrote about those issues:
NAION Linked To Zepbound, Mounjaro, Ozempic, Wegovy: 2026 News Update (5/22/26)
Ozempic Eye Side Effect NAION Warnings Update July 2026 (7/28/26)
Now for the two recent medical news articles about NAION with Ozempic, Wegovy, Mounjaro, or Zepbound use, as well as the present lack of any NAION and vision loss warnings here in the US:
- “GLP-1s may be linked to vision loss, but overall risk ‘very, very low’“, published online October 2, 2026, by Healio Primary Care Optometry News; and
- “GLP-1s and NAION: Do Patients Need a Warning?“, published online October 2, 2026, by Medscape Medical News.
From talking to numerous people who have vision loss due to NAION diagnosed while using Ozempic and Wegovy (which are both semaglutide-containing drugs), as well as Mounjaro and Zepbound (which are both tirzepatide-containing drugs), we can tell you that many of these people said they were disappointed there were no NAION and vision loss warnings. Moreover, some of those people were understandably angry about this failure by the responsible drug companies.
We have been investigating drug injury lawsuits against those drug companies for patients who have vision loss due to NAION with Ozempic, Wegovy, Mounjaro, or Zepbound use.
If you have been diagnosed with NAION due to Ozempic, Wegovy, Mounjaro, or Zepbound use, you may want to submit a Case Evaluation Form online to get a free review of your potential NAION lawsuit:
Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form
Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form
If you would prefer to discuss your potential NAION lawsuit with drug injury lawyer Tom Lamb, send him an email at TJL@LambLawOffice.com or call 910-256-2971.
[Read the article in full at Drug Injury Watch]Earlier articles about eye-related side effects of Ozempic, Wegovy, and Rybelsus:
- Mounjaro, Ozempic Vision Loss Lawsuits Filings Increase – 2026 News Reports
- NAION Cases Filed in Courts for Vision Loss Legal Compensation
- Ozempic Eye Side Effect NAION Warnings Update July 2026
- Semaglutide NAION Lawsuits in 2026 for Wegovy, Rybelsus, Ozempic Vision Loss
- NAION Linked To Zepbound Mounjaro, Ozempic, Wegovy: 2026 News Update
- Ozempic and Wegovy NAION Study 2026 Report: Two New Findings
- Ozempic-NAION Warnings Should Be In January 2026 Drug Label For New Pill Version
- Ozempic NAION Risk 200% Higher Than Some Other Diabetes Drugs
- Mounjaro and Ozempic NAION Vision Loss Lawsuits: Federal Court MDL No. 3163
- Ozempic Vision Loss Claims Compensation Payments Made in 2025
- Ozempic NAION Rate Higher in Recent 2025 Medical Study
- Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
- Link Between Ozempic and NAION Also Involves the Eye Disorder AION
- Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025
- Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
- Ozempic Eye Problems Caused by Semaglutide-Related NAION
- Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
- Ozempic Side Effects Include Eye Problems With Possible Vision Loss
Other articles about Ozempic, Wegovy, and Rybelsus by attorney Tom Lamb on the Side Effects Blog:
- Rybelsus Pancreatitis Warnings and Rybelsus Drug Injury Lawsuits
- A Rybelsus Blood Clots DVT Case
- Semaglutide-Related Blood Clots Cases: Ozempic, Wegovy, and Rybelsus
- Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic
- Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects
- Symptoms and Diagnosis of Weight-Loss Drugs Gastroparesis Side Effects for Ozempic, Rybelsus, Wegovy, and Trulicity
- Wegovy, Rybelsus, and Ozempic Linked to Gastroparesis by Medical Study
- Ozempic Intestinal Blockage and Obstruction Cases Increasing
- Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis
- Ozempic-Related Gastroparesis, Stomach Paralysis, Intestinal Blockages